ImQuest Receives $14.2 Million Five-Year Grant from NIH to Develop a Dual Compartment Topical Microbicide To Prevent HIV Transmission

August 1, 2012

ImQuest BioSciences, Inc. announced today the successful acquisition of funding from the National Institutes of Health to support the development of a safe and effective microbicide product that will be designed for both vaginal and rectal use. ImQuest and microbicide researchers from four major US-based universities, along with ImQuest's Korean partner Samjin Pharmaceutical Co. Ltd., will develop the highly innovative dual use combination product consisting of ImQuest’s highly potent pyrimidinedione inhibitor, IQP-0528, and Gilead’s tenofovir, which has already shown microbicidal activity in human clinical trials. The $14.2 million award for studies to be performed in the Integrated Preclinical/Clinical Program for HIV Topical Microbicides (IPCP-HTM), which is sponsored by the National Institute of Allergy and Infectious Disease (NIAID), will be led by Principal Investigator Robert W. Buckheit, Jr., Ph.D., President and Chief Executive Officer of ImQuest. Other participating scientific investigators from ImQuest include Anthony Ham, Ph.D., Scot Roberts, Ph.D., and Karen Buckheit, M.S. The project involves a consortium of Universities that contribute critical components to the program, including Johns Hopkins University, Centers for Disease Control, Miriam Hospital/Brown University, Duke University, and University of Pittsburgh. ImQuest and the research team hope to progress their DuoGel and Smart Suppository products to human clinical trials over the next two years, following the clinical evaluation of their IQP-0528 vaginal microbicide gel.

"This NIH award allows us to continue important prevention studies with IQP-0528, which we believe will be a highly effective topical microbicide product able to inhibit the sexual transmission of virus in both men and women," said Dr. Buckheit. "We are extremely pleased that the research team includes world-renowned scientists from many highly prestigious institutions and as a team we are intent on developing a product that will be of significant benefit to eliminating the threat of HIV from the world".

ImQuest BioSciences, based in Frederick, Maryland, is a contract research organization (CRO) focused on the development of agents for the prevention and treatment of infectious disease and cancer, as well as specialized capabilities to support the preformulation and formulation development for optimal product delivery. ImQuest's proprietary ImQuestSUCCESS platform for virology, microbiology, topical microbicides, and cancer has assisted their clients in expediting the development of products for clinical evaluation through rapid identification of candidates with a high probability of clinical success by reducing the risk associated with failure experienced during clinical development. ImQuest BioSciences and Samjin Pharmaceutical Co, Ltd. of Seoul, Korea, have a collaborative partnership to develop and market products for the treatment of infectious disease and cancer. More information on ImQuest BioSciences may be found on their website: www.imquestbio.com.

Return to Press Releases